Novel CTC Detection Method in Patients with Pancreatic Cancer Using High-Resolution Image Scanning
Authors:
- Takahiro ManabeTMTakahiro Manabe
- Tomoyuki OkumuraTOTomoyuki Okumura
- Kenji TerabayashiKTKenji Terabayashi
- Takahisa AkashiTATakahisa Akashi
- Teo Yi RuiTRTeo Yi Rui
- Yoshihisa NumataYNYoshihisa Numata
- Naoya TakedaNTNaoya Takeda
- Akane YamadaAYAkane Yamada
- Nana KimuraNKNana Kimura
- Mina FukasawaMFMina Fukasawa
- Tatsuhiro ArakiTATatsuhiro Araki
- Kosuke MoriKMKosuke Mori
Open Access
Abstract
Background/Objectives: Appropriate biomarkers are necessary for early diagnosis and multidisciplinary treatment of pancreatic ductal adenocarcinoma (PDAC). In recent years, the clinical utility of circulating tumor cells (CTC) as biomarkers for various can-cers has been reported; however, their detection rate in PDAC remains low, and clinical evidence is not yet established. CTC detection methods with high reliability and per-formance are essential for clarifying the importance of CTC in patients with PDAC. Methods: A total of 5 mL peripheral blood samples were collected from 38 patients newly diagnosed with PDAC and 17 healthy controls. Negatively enriched cells were immunofluorescently stained with EpCAM-phycoerythrin and cell surface vi-mentin-fluorescein isothiocyanate (CSV). Images were automatically captured using an all-in-one fluorescence microscope. Cellular regions were detected from these images, and the average luminance of the cellular regions was calculated. A total of 9086 and 1071 cell images were obtained from patients with PDAC and healthy controls, respec-tively. Results: In the EpCAM assay, a threshold that included 95% of healthy individuals was optimal for distinguishing patients with PDAC from healthy controls, with a sensi-tivity, specificity, and area under the curve of 0.74, 0.76, and 0.84, respectively. At this threshold, the CTC-positivity rate in patients with PDAC was 76.3%. Conversely, the CSV assay failed to demonstrate a valid threshold to distinguish patients with PDAC from healthy controls. No significant differences were found between CTC and clini-copathological features among patients with PDAC. Conclusions: The method using high-resolution image scanning has the potential to identify CTC with greater objectiv-ity by quantifying cell luminance values.Keywords
All Related Versions
Funding Information
- Japan Society for the Promotion of Science (21K08729, 24K11844)
This publication has 29 references indexed in Scilit:
- Efficacy of staging laparoscopy for resectable pancreatic cancer on imaging and the therapeutic effect of systemic chemotherapy for positive peritoneal cytologyJournal of Hepato-Biliary-Pancreatic Sciences, 2023
- Prognostic factors in conversion surgery following nab‐paclitaxel with gemcitabine and subsequent chemoradiotherapy for unresectable locally advanced pancreatic cancer: Results of a dual‐center studyAnnals of Gastroenterological Surgery, 2022
- A combination of circulating tumor cells and CA199 improves the diagnosis of pancreatic cancerJournal of Clinical Laboratory Analysis, 2022
- Vimentin-positive circulating tumor cells as a biomarker for diagnosis and treatment monitoring in patients with pancreatic cancerCancer Letters, 2019
- Clinical impact of circulating tumor cells and therapy response in pancreatic cancerEuropean Journal of Surgical Oncology, 2017
- Circulating tumor cells: clinical validity and utilityInternational Journal of Clinical Oncology, 2017
- Circulating tumour cells as a biomarker for diagnosis and staging in pancreatic cancerBritish Journal of Cancer, 2016
- Portal vein-circulating tumor cells predict liver metastases in patients with resectable pancreatic cancerTumor Biology, 2014
- The combination of the serum carbohydrate antigen 19-9 and carcinoembryonic antigen is a simple and accurate predictor of mortality in pancreatic cancer patientsSurgery Today, 2013
- Ep-CAM is a significant prognostic factor in pancreatic cancer patients by suppressing cell activityOncogene, 2011